PDMR Transaction Notification
CEO Anders Lundstrom acquired 575,000 ordinary shares at 3.7p per share.
Select text to share a quote on X · sign in to keep highlights & notes in your STX notes
London, UK, 13 February 2025: Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company specialising in iron deficiency, confirms that Mr Anders Lundstrom, Chief Executive Officer, acquired 575,000 Ordinary Shares in the Company on 13 February 2025 at a price of 3.7p per share. Mr Lundstrom now holds a beneficial interest in 585,000 Ordinary Shares.
The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a. | Name | Anders Lundstrom | ||||
| 2. | Reason for the notification | |||||
| a. | Position/status | Chief Executive Officer | ||||
| b. | Initial notification /Amendment | Initial | ||||
| a. | Name | Shield Therapeutics plc | ||||
| b. | LEI | 213800G74QWY15FC3W71 | ||||
| a. | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293 | ||||
| b. | Nature of the transaction | Acquisition of Ordinary Shares | ||||
| c. | Price(s) and volume(s) |
| ||||
| d. | Aggregated information · Aggregated volume · Price | 575,000 £21,275 | ||||
| f. | Place of the transaction | AIM |
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.